J. Lambea

3.6k total citations · 1 hit paper
26 papers, 1.0k citations indexed

About

J. Lambea is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, J. Lambea has authored 26 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in J. Lambea's work include Renal cell carcinoma treatment (7 papers), Colorectal Cancer Treatments and Studies (4 papers) and Colorectal Cancer Surgical Treatments (4 papers). J. Lambea is often cited by papers focused on Renal cell carcinoma treatment (7 papers), Colorectal Cancer Treatments and Studies (4 papers) and Colorectal Cancer Surgical Treatments (4 papers). J. Lambea collaborates with scholars based in Spain. J. Lambea's co-authors include Berta Sáez, A. Trés, Nuria Vilaboa, Manuel Arruebo, África González‐Fernández, Dolores Isla, Javier Martínez‐Trufero, Juan Jesús Cruz, J.L. González-Larriba and Pablo Maroto and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

J. Lambea

25 papers receiving 995 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Assessment of the Evolution of Cancer Treatment Therapies

2011 638 citations Manuel Arruebo, Nuria Vilaboa et al. Cancers profile →

Peers

Countries citing papers authored by J. Lambea

Since Specialization

Citations

This map shows the geographic impact of J. Lambea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Lambea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Lambea more than expected).

Fields of papers citing papers by J. Lambea

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Lambea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Lambea. The network helps show where J. Lambea may publish in the future.

Co-authorship network of co-authors of J. Lambea

This figure shows the co-authorship network connecting the top 25 collaborators of J. Lambea. A scholar is included among the top collaborators of J. Lambea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Lambea. J. Lambea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Diagnosis of Malnutrition According to GLIM Criteria Predicts Complications and 6-Month Survival in Cancer Outpatients 2022 ·Biomedicines ·(unknown), Diego Casas Deza, (unknown), (unknown), (unknown), (unknown), J. Lambea, (unknown), (unknown), Dolores Isla, José M. Arbones-Mainar	10
2	GLIM vs ESPEN criteria for the diagnosis of early malnutrition in oncological outpatients 2021 ·Clinical Nutrition ·(unknown), Diego Casas Deza, (unknown), (unknown), (unknown), (unknown), J. Lambea, (unknown), (unknown), Dolores Isla, José M. Arbones-Mainar	27
3	Correction to: SEOM clinical guidelines for the treatment of head and neck cancer (2020) 2021 ·Clinical & Translational Oncology ·Ricard Mesı́a, L. Iglesias, J. Lambea, Javier Martínez‐Trufero, Ainara Soria, Miren Taberna, José Trigo, (unknown), Almudena García‐Castaño, Juan Jesús Cruz	2
4	Comparation of different malnutrition screening tools according to GLIM criteria in cancer outpatients 2021 ·European Journal of Clinical Nutrition ·(unknown), Diego Casas Deza, (unknown), (unknown), (unknown), (unknown), J. Lambea, (unknown), (unknown), Dolores Isla, José M. Arbones-Mainar	12
5	Circulating Levels of the Interferon-γ-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic Therapy 2021 ·Cancers ·Emilio Esteban, Francisco Expósito, Guillermo Crespo, J. Lambea, Álvaro Pinto, Javier Puente, José Ángel Arranz, Miriam Redrado, Cristina Rodríguez‐Antona, Carlos de Andrea, M. López-Brea, Esther Redín, Ángel Rodríguez, Diego Serrano, Jorge García, Enrique Grande, Daniel Castellano, Alfonso Calvo	13
6	SEOM clinical guidelines for the treatment of head and neck cancer (2020) 2021 ·Clinical & Translational Oncology ·Ricard Mesı́a, L. Iglesias, J. Lambea, Javier Martínez‐Trufero, Ainara Soria, Miren Taberna, José Trigo, (unknown), Almudena García‐Castaño, Juan Jesús Cruz	64
7	Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE 2020 ·Therapeutic Advances in Medical Oncology ·Javier Puente, Urbano Anido, Miguel Ángel Climent, Enrique González‐Billalabeitia, Núria Laínez, J. Lambea, Pablo Maroto, María José Méndez-Vidal, A. Montesa, Ángel Rodríguez, (unknown), Aranzazu González del Alba	2
8	Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma 2018 ·BMC Pharmacology and Toxicology ·María José Méndez-Vidal, (unknown), Urbano Anido, Isabel Chirivella, (unknown), E. Fernández-Parra, Marta Guix, Carolina Hernández, J. Lambea, A. Montesa, Álvaro Pinto, (unknown), Enrique Gallardo	20
9	SPAZO2 (SOGUG): Comparative effectiveness of everolimus (Ev) vs axitinib (Ax) as second-line after first-line pazopanib (1stPz) in metastatic renal carcinoma (mRC) 2017 ·Annals of Oncology ·(unknown), Begoña Pérez‐Valderrama, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), J.L. González-Larriba, (unknown), J. Lambea, (unknown), (unknown), Juan Antonio Virizuela Echaburu, (unknown), (unknown), (unknown), Javier Cassinello, J.M. Jurado	1
10	The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma 2016 ·Current Oncology Reports ·J. Lambea, Urbano Anido, (unknown), (unknown), A. Montesa, Juan Manuel Sepúlveda-Sánchez, Emilio Esteban	6
11	Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action 2016 ·Targeted Oncology ·Ignacio Durán, J. Lambea, Pablo Maroto, J.L. González-Larriba, (unknown), Sergio Granados‐Principal, Mariona Graupera, Berta Sáez, Ana Vivancos, Oriol Casanovas	79
12	Quality of life and supportive care for patients with metastatic renal cell carcinoma 2012 ·Cancer and Metastasis Reviews ·J. Lambea, (unknown), Núria Laínez, M. Lázaro, Luis León‐Mateos, Ángel Rodríguez, (unknown), Emilio Esteban	10
13	Assessment of the Evolution of Cancer Treatment Therapies breakdown → 2011 ·Cancers ·Manuel Arruebo, Nuria Vilaboa, Berta Sáez, J. Lambea, A. Trés, (unknown), África González‐Fernández	638
14	Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment 2010 ·British Journal of Cancer ·(unknown), Javier Martínez‐Trufero, Dolores Isla, (unknown), Antonio Irigoyen López, Ricardo Hitt, (unknown), J. Lambea, María José Lecumberri, Juan Jesús Cruz	38
15	Evaluation of neurological symptoms in oncologic patients at the emergency department 2009 ·Journal of Clinical Oncology ·(unknown), Derrick Lopez, Marieberta Vidal, (unknown), Sérgio Serrano, (unknown), E. Millastre, (unknown), J. Lambea, A. Trés	1
16	Fever in cancer patients as a cause of attendance in emergency room 2009 ·Journal of Clinical Oncology ·Marieberta Vidal, (unknown), Sérgio Serrano, (unknown), (unknown), Daniel Aparicio-López, E. Millastre, (unknown), J. Lambea, A. Trés	0
17	Dendritic cell uptake of iron‐based magnetic nanoparticles 2008 ·Cell Biology International ·Gerardo F. Goya, Iván Marcos-Campos, Rodrigo Fernández‐Pacheco, Berta Sáez, (unknown), Laura Asín, J. Lambea, (unknown), José Mayordomo, Luis Larrad, M. R. Ibarra, A. Trés	42
18	Gemcitabine/Capecitabine in Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes 2005 ·Clinical Breast Cancer ·(unknown), José Mayordomo, (unknown), (unknown), Eugenia Ortega, Eduardo Polo, J. Lambea, Dolores Isla, (unknown), P. Escudero, A. Trés	22
19	Abordaje terapéutico del carcinoma de pulmón no microcítico avanzado: ¿estamos "avanzando"? 2005 ·Dolores Isla, (unknown), (unknown), (unknown), J. Lambea, Raquel Andrés	2
20	Preoperative chemoradiation with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma 2004 ·Journal of Clinical Oncology ·Vicente Alonso, Antonieta Salud, P. Escudero, (unknown), M. Mira, (unknown), J. Lambea, (unknown), A. Trés, A. Antón	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact